RU2019103083A - МУТАЦИИ ErbB3 ПРИ РАКЕ - Google Patents
МУТАЦИИ ErbB3 ПРИ РАКЕ Download PDFInfo
- Publication number
- RU2019103083A RU2019103083A RU2019103083A RU2019103083A RU2019103083A RU 2019103083 A RU2019103083 A RU 2019103083A RU 2019103083 A RU2019103083 A RU 2019103083A RU 2019103083 A RU2019103083 A RU 2019103083A RU 2019103083 A RU2019103083 A RU 2019103083A
- Authority
- RU
- Russia
- Prior art keywords
- mutation
- erbb3
- cancer
- antibody
- antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (37)
1. Вещество для выявления ErbB3-обусловленного рака желудочно-кишечного тракта для применения в образце ткани желудочно-кишечного тракта, полученном у пациента, содержащее полинуклеотидный агент, способный специфически связываться с ErbB3 мутационным кодоном в нуклеотидной последовательности ErbB3, где мутационный кодон кодирует i) аминокислотную заместительную мутацию в SEQ ID NO: 2 в положении, выбранном из группы из 809, 232, 262, 325, 60, 111, 135, 295, 406, 453 и 1164, или ii) стоп-кодон в SEQ ID NO: 2 в положении 193, и где полинуклеотидный агент содержит полинуклеотид, комплементарный формуле
где
X отсутствует, если а равно 0, или X представляет собой последовательность нуклеиновой кислоты, содержащую 1-250 нуклеотидов последовательности нуклеиновой кислоты ErbB3, если а равно 1-250;
Y является ErbB3 мутационным кодоном; и
Z отсутствует, если а равно 0, или Z представляет собой последовательность нуклеиновой кислоты, содержащую 1-250 нуклеотидов последовательности нуклеиновой кислоты ErbB3, если b равно 1-250; и
и где суммарная длина полинуклеотида с формулой Xa-Y-Zb составляет по крайней мере семь нуклеотидов в длину и меньше 250 нуклеотидов в длину.
2. Вещество для выявления рака по п. 1, отличающееся тем, что нуклеотидная последовательность ErbB3 содержит SEQ ID NO: 230 или 1.
3. Вещество для выявления рака по любому из пп. 1-2, где агент для обнаружения конъюгирован с детектируемой меткой.
4. Вещество для выявления рака по п. 3, где детектируемая метка выбрана из группы, состоящей из радиоизотопа, флуоресцентной метки, биолюминесцентной метки и ферментной метки.
5. Вещество для выявления рака по любому из пп. 1-4, где мутация выбрана из Q809R, A232V, Р262Н, P262S, G325R, M60K, Y111C, R135L, V295A, M406K, М406Т, R453H и T1164A и стоп-кодона в положении 193.
6. Способ определения наличия ErbB3-обусловленного рака желудочно-кишечного тракта у пациента, включающий выявление в биологическом образце, полученном из желудочно-кишечного тракта пациента, заместительной мутации в нуклеотидной последовательности, кодирующей ErbB3, где заместительная мутация приводит к i) аминокислотной замене в SEQ ID NO: 2 в положении, выбранном из группы из 104, 809, 232, 262, 284, 325, 60, 111, 135, 295, 406, 453 и 1164, или ii) стоп-кодону в SEQ ID NO: 2 в положении 193, и где указанная заместительная мутация указывает на наличие у пациента ErbB3-обусловленного рака желудочно-кишечного тракта.
7. Способ по п. 6, где мутация выбрана из V104M, V104L, Q809R, A232V, Р262Н, P262S, G284R, G325R, M60K, Y111C, R135L, V295A, M406K, М406Т, R453H и Т1164А, или стоп-кодона в положении 193.
8. Способ по п. 6 или 7, дополнительно включающий введение терапевтического средства пациенту, идентифицированного как имеющей ErbB3-обусловленный рак желудочно-кишечного тракта.
9. Способ по п. 8, отличающийся тем, что терапевтическое средство является ингибитором ErbB.
10. Способ по п. 9, отличающийся тем, что ингибитор ErbB выбран из группы, состоящей из антагониста EGFR, антагониста ErbB2, антагониста ErbB3, антагониста ErbB4 и антагониста EGFR/ErbB3.
11. Способ по п. 10, отличающийся тем, что ингибитор является низкомолекулярным ингибитором.
12. Способ по п. 10, отличающийся тем, что антагонист является антагонистическим антителом.
13. Способ по п. 12, отличающийся тем, что антитело выбрано из группы, состоящей из моноклонального антитела, биспецифического антитела, химерного антитела, антитела человека, гуманизированного антитела и фрагмента антитела.
14. Вещество для выявления рака по п. 1 или способ по п. 6, отличающиеся тем, что рак желудочно-кишечного тракта является раком желудка или раком толстой кишки.
15. Способ по п. 6, дополнительно включающий получение образца от пациента.
16. Способ по п. 6, отличающийся тем, что выявление включает амплификацию или секвенирование мутации и выявление мутации или ее последовательности.
17. Способ по п. 16, отличающийся тем, что амплификация включает смешивание амплификационного праймера или пары амплификационных праймеров с нуклеотидной матрицей, выделенной из образца.
18. Способ по п. 17, отличающийся тем, что праймер или пара праймеров является комплементарной либо частично комплементарной участку близлежащему к или содержащему указанную мутацию и способен инициировать полимеризацию нуклеиновой кислоты полимеразой на нуклеотидной матрице.
19. Способ по п. 17, дополнительно включающий удлинение праймера или пары праймеров в реакции полимеризации ДНК, включающей полимеразу и нуклеотидную матрицу, с образованием ампликона.
20. Способ по п. 16, отличающийся тем, что заместительную мутацию выявляют способом, который включает один или более из следующих этапов: секвенирование мутации в геномной ДНК, выделенной из биологического образца, гибридизацию мутации или ее ампликона с матрицей, обработку мутации или ее ампликона рестрикционным ферментом или ПЦР амплификацию мутации в режиме настоящего времени.
21. Способ по п. 16, включающий частичное либо полное секвенирование мутации в нуклеиновой кислоте, выделенной из биологического образца.
22. Способ по п. 16, отличающийся тем, что амплификация включает проведение полимеразной цепной реакции (ПЦР), ПЦР с обратной транскриптазой (ПЦР-ОТ) или лигазной цепной реакции (ЛЦР) с участием нуклеиновой кислоты, выделенной из биологического образца в качестве матрицы в ПЦР, ПЦР-ОТ или ЛЦР.
23. Применение ингибитора ErbB в способе лечения ErbB3-обусловленного рака желудочно-кишечного тракта у нуждающегося в этом пациента, включающем:
a) выявление в биологическом образце, полученном из желудочно-кишечного тракта пациента, заместительной мутации в нуклеотидной последовательности, кодирующей ErbB3, где заместительная мутация приводит к i) аминокислотной замене в SEQ ID NO: 2 в положении, выбранном из группы, состоящей из 104, 809, 232, 262, 284, 325, 60, 111, 135, 295, 406, 453 и 1164, или ii) стоп-кодону в SEQ ID NO: 2 в положении 193, и где указанная заместительная мутация указывает на наличие у пациента ErbB3-обусловленного рака желудочно-кишечного тракта; и
b) введение указанному пациенту ингибитора ErbB.
24. Применение по п. 23, где мутация выбрана из V104M, V104L, Q809R, A232V, Р262Н, P262S, G284R, G325R, M60K, Y111C, R135L, V295A, M406K, М406Т, R453H и T1164A, или стоп-кодона в положении 193.
25. Применение по п. 23 или 24, отличающийся тем, что ингибитор ErbB выбран из группы, состоящей из антагониста EGFR, антагониста ErbB2, антагониста ErbB3, антагониста ErbB4 и антагониста EGFR/ErbB3.
26. Применение по п. 25, отличающийся тем, что ингибитор является низкомолекулярным ингибитором.
27. Применение по п. 25, отличающийся тем, что антагонист является антагонистическим антителом.
28. Применение по п. 27, отличающийся тем, что антитело выбрано из группы, состоящей из моноклонального антитела, биспецифического антитела, химерного антитела, антитела человека, гуманизированного антитела и фрагмента антитела.
29. Применение по п. 23, отличающийся тем, что рак желудочно-кишечного тракта является раком желудка или раком толстой кишки.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161629951P | 2011-11-30 | 2011-11-30 | |
US61/629,951 | 2011-11-30 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014126098A Division RU2014126098A (ru) | 2011-11-30 | 2012-11-29 | МУТАЦИИ ErbB3 ПРИ РАКЕ |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2019103083A true RU2019103083A (ru) | 2019-03-22 |
Family
ID=47358263
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014126098A RU2014126098A (ru) | 2011-11-30 | 2012-11-29 | МУТАЦИИ ErbB3 ПРИ РАКЕ |
RU2019103083A RU2019103083A (ru) | 2011-11-30 | 2012-11-29 | МУТАЦИИ ErbB3 ПРИ РАКЕ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014126098A RU2014126098A (ru) | 2011-11-30 | 2012-11-29 | МУТАЦИИ ErbB3 ПРИ РАКЕ |
Country Status (14)
Country | Link |
---|---|
US (1) | US20130195870A1 (ru) |
EP (1) | EP2785864A2 (ru) |
JP (2) | JP2015500638A (ru) |
KR (1) | KR20140098834A (ru) |
CN (2) | CN104271761B (ru) |
AU (1) | AU2012346540C1 (ru) |
BR (1) | BR112014012979A2 (ru) |
CA (1) | CA2857114A1 (ru) |
HK (1) | HK1201301A1 (ru) |
IL (1) | IL232713A0 (ru) |
MX (1) | MX2014006529A (ru) |
RU (2) | RU2014126098A (ru) |
SG (1) | SG11201402510TA (ru) |
WO (1) | WO2013081645A2 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10221230B2 (en) | 2013-02-25 | 2019-03-05 | Ohio State Innovation Foundation | HER-1, HER-3 and IGF-1R compositions and uses thereof |
WO2016038609A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
AU2015313811A1 (en) | 2014-09-08 | 2017-04-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) |
WO2018050848A1 (en) * | 2016-09-15 | 2018-03-22 | Universität Stuttgart | Antigen binding protein against her3 |
CN112912109A (zh) * | 2018-09-20 | 2021-06-04 | 第一三共株式会社 | 通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症 |
CN111187835B (zh) * | 2019-02-02 | 2023-03-31 | 中国科学院上海营养与健康研究所 | 胰腺癌的靶点erbb2及其在诊断和治疗中的应用 |
Family Cites Families (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003211A (en) | 1934-09-05 | 1935-05-28 | Royal Typewriter Co Inc | Typewriting machine |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4935341A (en) | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
EP0412116B1 (en) | 1988-04-18 | 1995-11-29 | Oncogene Science, Inc. | Detection of neu gene expression and products |
DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech Inc | Her2 extrazellulare domäne |
US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US6884418B1 (en) | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
DE69033842T2 (de) | 1989-08-04 | 2002-06-20 | Schering Ag | Äusserliche domäne von c-erbb-2:gp75 |
WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
JP3208427B2 (ja) | 1989-09-29 | 2001-09-10 | オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド | ヒトの生物学的流体中のneu関連タンパク質の検出及び定量 |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
AU662311B2 (en) | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
CA2096417C (en) | 1991-08-22 | 2000-10-10 | Sarah S. Bacus | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5288477A (en) | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993012220A1 (en) | 1991-12-12 | 1993-06-24 | Berlex Laboratories, Inc. | RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2 |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
AU5355594A (en) | 1992-10-09 | 1994-05-09 | Oncor, Inc. | Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
PT616812E (pt) | 1993-03-24 | 2000-04-28 | Berlex Biosciences | Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro |
AU6527894A (en) | 1993-03-30 | 1994-10-24 | Trustees Of The University Of Pennsylvania, The | Prevention of tumors with monoclonal antibodies against (neu) |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5846749A (en) | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
ATE170082T1 (de) | 1994-11-10 | 1998-09-15 | Univ Eberhard Karls | Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen |
WO1996016673A1 (en) | 1994-12-02 | 1996-06-06 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
US5783404A (en) | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
JP4146514B2 (ja) | 1995-07-06 | 2008-09-10 | ノバルティス アクチエンゲゼルシャフト | ピロロピリミジン類およびその製造方法 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
SI0892789T2 (sl) | 1996-04-12 | 2010-03-31 | Warner Lambert Co | Ireverzibilni inhibitorji tirozin kinaz |
EP1736554B1 (en) | 1996-05-29 | 2013-10-09 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US5925519A (en) | 1996-06-03 | 1999-07-20 | The Regents Of The University Of California | Genetic alterations associated with prostate cancer |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
CA2269204C (en) | 1996-10-18 | 2012-01-24 | Genentech, Inc. | Anti-erbb2 antibodies |
WO1998018489A1 (en) | 1996-10-30 | 1998-05-07 | The Uab Research Foundation | Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies |
US6468547B1 (en) | 1996-10-30 | 2002-10-22 | Uab Research Foundation | Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies |
PT1864999E (pt) | 1996-11-27 | 2009-06-25 | Genentech Inc | Purificação por afinidade de um polipéptido numa matriz de proteína a |
EP1012275A1 (en) | 1997-01-31 | 2000-06-28 | University Of Rochester | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
US20020076695A1 (en) | 1997-04-04 | 2002-06-20 | Jeffrey S. Ross | Methods for treating prostate cancer |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
WO1999019488A1 (en) | 1997-10-15 | 1999-04-22 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
CA2306155A1 (en) | 1997-11-06 | 1999-05-20 | Philip Frost | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6358682B1 (en) | 1998-01-26 | 2002-03-19 | Ventana Medical Systems, Inc. | Method and kit for the prognostication of breast cancer |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
JP2002507404A (ja) | 1998-03-27 | 2002-03-12 | ジェネンテク・インコーポレイテッド | Apo−2リガンド−抗HER−2抗体相乗作用 |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
DE69936946T2 (de) | 1998-05-06 | 2008-05-15 | Genentech, Inc., South San Francisco | Reinigung von Antikörpern durch Ionenaustauschchromatographie |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
JP3687900B2 (ja) | 1998-11-19 | 2005-08-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | チロシンキナーゼの不可逆的阻害剤であるn−[4−(3−クロロ−4−フルオロフェニルアミノ)−7−(3−モルホリン−4−イルプロポキシ)キナゾリン−6−イル]アクリルアミド |
ATE425749T1 (de) | 1999-01-27 | 2009-04-15 | Cornell Res Foundation Inc | Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs |
US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
WO2000069460A1 (en) | 1999-05-14 | 2000-11-23 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
CA2383493C (en) | 1999-06-25 | 2010-08-10 | Genentech, Inc. | Treating prostate cancer with anti-erbb2 antibodies |
EP1191944A2 (en) | 1999-06-25 | 2002-04-03 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
CH694589A5 (de) | 1999-06-25 | 2005-04-15 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern. |
GB9917012D0 (en) | 1999-07-20 | 1999-09-22 | Pharmacia & Upjohn Spa | Combined preparations comprising antitumor agents |
CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
NZ517150A (en) | 1999-08-27 | 2005-01-28 | Genentech Inc | Dosages for treatment with anti-ErbB2 antibodies |
EP1214595A2 (en) | 1999-09-22 | 2002-06-19 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
GB9925958D0 (en) | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
US20020041865A1 (en) | 2000-01-20 | 2002-04-11 | Richard Austin | Methods for treating tumors |
JP2003525252A (ja) | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Her2抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US6767541B2 (en) | 2000-03-20 | 2004-07-27 | The Regents Of The University Of California | HER-2/neu overexpression abrogates growth inhibitory pathways |
GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
AU2001246850A1 (en) | 2000-04-06 | 2001-10-23 | Kyowa Hakko Kogyo Co. Ltd. | Diagnostics and remedies for rheumatoid arthritis |
CA2409652A1 (en) | 2000-05-15 | 2001-11-22 | Giorgio Massimini | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
DK1282443T3 (da) | 2000-05-19 | 2010-01-04 | Genentech Inc | Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi |
EP1313880A2 (en) | 2000-05-30 | 2003-05-28 | PE Corporation (NY) | Methods for detecting target nucleic acids using coupled ligation and amplification |
GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
DE10036735C2 (de) | 2000-07-27 | 2002-07-11 | Infineon Technologies Ag | Multipliziererschaltung mit Offset-Kompensation und Quadrikorrelator |
TWI317285B (en) | 2000-07-28 | 2009-11-21 | Dainippon Sumitomo Pharma Co | New use and kit for remedies for cancer |
AU2001295002B2 (en) | 2000-08-09 | 2007-05-31 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
CN1488002A (zh) | 2000-12-01 | 2004-04-07 | ��˹��ŵ�� | 测定表皮生长因子受体和HER2-neu的基因表达及其水平与存活率之间相关性的方法 |
US6602670B2 (en) | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US7005278B2 (en) | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
US6582919B2 (en) | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
US20020142328A1 (en) | 2000-12-01 | 2002-10-03 | Danenberg Kathleen D. | Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors |
WO2002045653A2 (en) | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
KR100983997B1 (ko) | 2001-01-09 | 2010-09-28 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
WO2002087619A1 (fr) | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
KR20040029975A (ko) | 2001-05-08 | 2004-04-08 | 메르크 파텐트 게엠베하 | 항-egfr 항체 및 항호르몬제를 이용한 병용 요법 |
ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
US7125680B2 (en) * | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
WO2003012072A2 (en) | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
US20030068318A1 (en) | 2001-09-28 | 2003-04-10 | O'brien Timothy | Treatment of uterine serous papillary cancer |
US20030096823A1 (en) | 2001-11-16 | 2003-05-22 | Beryl Asp | Method for the treatment of cardiotoxicity induced by antitumor compounds |
US20030119004A1 (en) | 2001-12-05 | 2003-06-26 | Wenz H. Michael | Methods for quantitating nucleic acids using coupled ligation and amplification |
US20030175845A1 (en) | 2002-03-13 | 2003-09-18 | Kalbag Suresh M. | Use of sulfitolysis in high performance peptide mapping |
EP1492568A1 (en) | 2002-04-08 | 2005-01-05 | SmithKline Beecham Corporation | Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
CA2481515C (en) | 2002-04-10 | 2013-10-01 | Genentech, Inc. | Anti-her2 antibody variants |
ITTO20020340A1 (it) | 2002-04-19 | 2003-10-20 | Biother Di Contardi Gabriella | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
US20030202973A1 (en) | 2002-04-29 | 2003-10-30 | Dr. George Pieczenik | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists |
DK2263691T3 (da) | 2002-07-15 | 2012-10-22 | Hoffmann La Roche | Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4) |
LT1543038T (lt) | 2002-09-11 | 2017-07-10 | Genentech, Inc. | Baltymo gryninimas |
EP1572972A4 (en) | 2002-11-21 | 2007-11-21 | Genentech Inc | THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES |
WO2004087207A2 (en) | 2003-03-27 | 2004-10-14 | Georgetown University | Method for inducing apoptosis and aneuploidy regression in cancer cells |
WO2008061213A2 (en) * | 2006-11-16 | 2008-05-22 | Genentech, Inc. | Genetic variations associated with tumors |
US20110008347A1 (en) * | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
SG174378A1 (en) | 2009-03-20 | 2011-10-28 | Genentech Inc | Bispecific anti-her antibodies |
MY161909A (en) | 2009-12-22 | 2017-05-15 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
-
2012
- 2012-11-29 RU RU2014126098A patent/RU2014126098A/ru not_active Application Discontinuation
- 2012-11-29 JP JP2014544721A patent/JP2015500638A/ja active Pending
- 2012-11-29 BR BR112014012979-7A patent/BR112014012979A2/pt not_active IP Right Cessation
- 2012-11-29 KR KR1020147017927A patent/KR20140098834A/ko not_active Application Discontinuation
- 2012-11-29 EP EP12801651.6A patent/EP2785864A2/en not_active Withdrawn
- 2012-11-29 AU AU2012346540A patent/AU2012346540C1/en not_active Ceased
- 2012-11-29 CA CA2857114A patent/CA2857114A1/en not_active Abandoned
- 2012-11-29 US US13/694,413 patent/US20130195870A1/en not_active Abandoned
- 2012-11-29 RU RU2019103083A patent/RU2019103083A/ru not_active Application Discontinuation
- 2012-11-29 SG SG11201402510TA patent/SG11201402510TA/en unknown
- 2012-11-29 MX MX2014006529A patent/MX2014006529A/es unknown
- 2012-11-29 CN CN201280067318.0A patent/CN104271761B/zh not_active Expired - Fee Related
- 2012-11-29 CN CN201710084997.7A patent/CN106987620A/zh active Pending
- 2012-11-29 WO PCT/US2012/000568 patent/WO2013081645A2/en active Application Filing
-
2014
- 2014-05-20 IL IL232713A patent/IL232713A0/en unknown
-
2015
- 2015-02-16 HK HK15101705.7A patent/HK1201301A1/xx not_active IP Right Cessation
-
2018
- 2018-01-05 JP JP2018000704A patent/JP2018085998A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2785864A2 (en) | 2014-10-08 |
NZ625380A (en) | 2016-10-28 |
AU2012346540C1 (en) | 2019-07-04 |
CN104271761A (zh) | 2015-01-07 |
KR20140098834A (ko) | 2014-08-08 |
SG11201402510TA (en) | 2014-06-27 |
JP2015500638A (ja) | 2015-01-08 |
WO2013081645A2 (en) | 2013-06-06 |
IL232713A0 (en) | 2014-07-31 |
AU2012346540A1 (en) | 2014-07-03 |
BR112014012979A2 (pt) | 2020-10-20 |
AU2012346540B2 (en) | 2018-09-13 |
RU2014126098A (ru) | 2016-01-27 |
CN104271761B (zh) | 2017-03-15 |
MX2014006529A (es) | 2014-11-25 |
HK1201301A1 (en) | 2015-08-28 |
US20130195870A1 (en) | 2013-08-01 |
JP2018085998A (ja) | 2018-06-07 |
CA2857114A1 (en) | 2013-06-06 |
WO2013081645A3 (en) | 2013-07-25 |
CN106987620A (zh) | 2017-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2019103083A (ru) | МУТАЦИИ ErbB3 ПРИ РАКЕ | |
ES2346589T3 (es) | Metodo para la deteccion de mutaciones en egfr en muestras de sagre. | |
CN105087771B (zh) | 鉴定样品中微生物种类的方法及其试剂盒 | |
EP2504433A2 (en) | Allelic ladder loci | |
US20100248310A1 (en) | Method of dna amplification | |
JP2015500638A5 (ru) | ||
JP2016510982A5 (ru) | ||
WO2011104695A2 (en) | Detection of kras mutation in exon 2 by allele specific real time quantitative pcr (as-qpcr) | |
Kusumawati et al. | Use of reverse transcription loop-mediated isothermal amplification combined with lateral flow dipstick for an easy and rapid detection of Jembrana disease virus | |
KR101287431B1 (ko) | 표적 유전자의 다양한 변이가 존재하는 유전자 영역을 증폭하기 위한 프라이머 조성물, 이를 이용한 표적 유전자 증폭 방법 및 이를 포함하는 pcr 증폭 키트 그리고 이를 이용한 표적 유전자의 유전자형 분석방법 | |
CN105567698B (zh) | 鳐血管生成抑制因子1的适配子k19及其筛选方法和应用 | |
JP6756835B2 (ja) | ウイルス性出血性敗血症ウイルスの遺伝子変異の検出方法 | |
EP3870720A1 (en) | Use of long non-coding rna for the diagnosis of prostate cancer | |
KR101727598B1 (ko) | Pna 프로브 및 융해곡선분석을 이용한 미토콘드리아 dna의 snp 분석방법 | |
JP5692774B2 (ja) | 一塩基多型を検出する方法および試薬キット | |
JP5243829B2 (ja) | メチル化dnaの解析方法 | |
KR101644776B1 (ko) | 참돔 이리도바이러스 검출용 유전자 마커, 및 이를 이용한 원인바이러스의 검출 방법 | |
ES2294346T3 (es) | Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage. | |
JP2004344065A (ja) | オリゴヌクレオチド及びそれを用いた結核菌群の検出方法 | |
CN111615561B (zh) | 单核苷酸多态性检测用寡核苷酸探针和顺式-反式判别方法 | |
CN107937604B (zh) | 检测传染性肌肉坏死病毒的遗传标志物及使用该遗传标志物检测传染性肌肉坏死病毒的方法 | |
EP2229454A1 (en) | Assay for prediction of response to met antagonists | |
CN107385065B (zh) | 扩增核酸的方法及其应用 | |
CN105713081B (zh) | 鳐血管生成抑制因子1的适配子k17及其筛选方法和应用 | |
CN105669852B (zh) | 鳐血管生成抑制因子1的适配子k10及其筛选方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20151130 |